Benchmarking UK Lynch syndrome colonoscopy surveillance: quality metrics and diagnostic yield from the National Endoscopy Database
- 1Centre for Familial Intestinal Cancer St Mark's Hospital and Academic Institute London United Kingdom of Great Britain and Northern Ireland
- 2Department of Surgery and Cancer Imperial College London London United Kingdom of Great Britain and Northern Ireland
- 3Department of Gastroenterology Northumbria Healthcare NHS Foundation Trust North Shields United Kingdom of Great Britain and Northern Ireland
Abstract
Background: Colonoscopy quality and diagnostic outcomes in Lynch syndrome have historically been heterogeneous. Following the introduction of the Lynch syndrome Bowel Cancer Screening Programme (BCSP), we assessed colonoscopy quality and diagnostic yield in Lynch syndrome using the National Endoscopy Database (NED), comparing outcomes between BCSP and non-BCSP providers.
Methods: We performed a cross-sectional analysis of UK Lynch syndrome colonoscopies from NED between June 2024 and June 2025. Colonoscopy quality indicators and endoscopic detection rates for polyp (PDR) and advanced neoplasia (eANDR; polyps ≥10 mm or cancer; histopathology linkage was unavailable) were calculated and compared between BCSP and non-BCSP providers. Factors associated with neoplasia detection were identified using logistic regression.
Results: Among 3196 colonoscopies, most were performed in England (90.2%), with 34.1% undertaken within BCSP. Overall colonoscopy quality was high: 97.6% were complete, 89.0% had adequate bowel preparation, and 96.3% had adequate tolerance. BCSP procedures demonstrated higher rates of completion (98.5% vs. 97.1%; P = 0.02) and adequate bowel preparation (92.7% vs. 86.7%; P < 0.001) than non-BCSP colonoscopies. PDR and eANDR were 46.8% and 4.7%, respectively, and were higher in BCSP than non-BCSP procedures (PDR 53.7% vs. 43.3%; eANDR 5.7% vs. 3.9%). Higher polyp detection was associated with increasing age (odds ratio [OR] 1.03, 95%CI 1.03–1.04), male gender (OR 1.48, 95%CI 1.26–1.73), BCSP status (OR 1.50, 95%CI 1.28–1.77), adequate bowel preparation (OR 1.81, 95%CI 1.40–2.34), and England nation (OR 1.99, 95%CI 1.22–3.36).
Conclusions: Our NED evaluation demonstrated high colonoscopy performance in Lynch syndrome, with superior quality and endoscopic yield in BCSP procedures, supporting national integration of surveillance to establish Lynch syndrome-specific quality benchmarks.
Related
- Diagnostic Yield of Opportunistic Upper Gastrointestinal Endoscopy During Elective Colonoscopy in Asymptomatic Patients: A Retrospective Cross-Sectional Study.
- Beyond White-Light Colonoscopy: Water Exchange, Image-Enhanced Endoscopy, and Artificial Intelligence for Colorectal Neoplasia Detection—From Single Tools to Combined Strategies: A Scoping Review
- Can Routine Preoperative Endoscopy and Colonoscopy Be Meaningful for the Surgery and Postoperative Course of Patients with Advanced Ovarian Cancer? A Single-Centre Retrospective Cohort Study.
- Risk of Advanced Colorectal Neoplasia among Patients Undergoing Repeated Colonoscopy Surveillance: A Two-Center Study.
- Concordancia diagnóstica entre la cápsula endoscópica y la enteroscopía de doble balón en la hemorragia digestiva de intestino medio en un hospital de referencia en Perú Diagnostic Agreement Between Capsule Endoscopy and Double-Balloon Enteroscopy in Mid-Gut Gastrointestinal Bleeding at a Referral Hospital in Peru
BibTeX
@article{poo2026benchmarking,
title = {{Benchmarking UK Lynch syndrome colonoscopy surveillance: quality metrics and diagnostic yield from the National Endoscopy Database}},
author = {Stephanie X. W. Poo and Thomas Lee and Amanda J. Cross and Kevin J. Monahan},
journal = {Endoscopy},
year = {2026},
month = aug,
doi = {10.1055/a-2939-3426},
url = {https://doi.org/10.1055/a-2939-3426},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Benchmarking UK Lynch syndrome colonoscopy surveillance: quality metrics and diagnostic yield from the National Endoscopy Database
AU - Stephanie X. W. Poo
AU - Thomas Lee
AU - Amanda J. Cross
AU - Kevin J. Monahan
PY - 2026
DA - 2026/08/31
JO - Endoscopy
DO - 10.1055/a-2939-3426
UR - https://doi.org/10.1055/a-2939-3426
AB - Background: Colonoscopy quality and diagnostic outcomes in Lynch syndrome have historically been heterogeneous. Following the introduction of the Lynch syndrome Bowel Cancer Screening Programme (BCSP), we assessed colonoscopy quality and diagnostic yield in Lynch syndrome using the National Endoscopy Database (NED), comparing outcomes between BCSP and non-BCSP providers. Methods: We performed a cross-sectional analysis of UK Lynch syndrome colonoscopies from NED between June 2024 and June 2025. Colonoscopy quality indicators and endoscopic detection rates for polyp (PDR) and advanced neoplasia (eANDR; polyps ≥10 mm or cancer; histopathology linkage was unavailable) were calculated and compared between BCSP and non-BCSP providers. Factors associated with neoplasia detection were identified using logistic regression. Results: Among 3196 colonoscopies, most were performed in England (90.2%), with 34.1% undertaken within BCSP. Overall colonoscopy quality was high: 97.6% were complete, 89.0% had adequate bowel preparation, and 96.3% had adequate tolerance. BCSP procedures demonstrated higher rates of completion (98.5% vs. 97.1%; P = 0.02) and adequate bowel preparation (92.7% vs. 86.7%; P < 0.001) than non-BCSP colonoscopies. PDR and eANDR were 46.8% and 4.7%, respectively, and were higher in BCSP than non-BCSP procedures (PDR 53.7% vs. 43.3%; eANDR 5.7% vs. 3.9%). Higher polyp detection was associated with increasing age (odds ratio [OR] 1.03, 95%CI 1.03–1.04), male gender (OR 1.48, 95%CI 1.26–1.73), BCSP status (OR 1.50, 95%CI 1.28–1.77), adequate bowel preparation (OR 1.81, 95%CI 1.40–2.34), and England nation (OR 1.99, 95%CI 1.22–3.36). Conclusions: Our NED evaluation demonstrated high colonoscopy performance in Lynch syndrome, with superior quality and endoscopic yield in BCSP procedures, supporting national integration of surveillance to establish Lynch syndrome-specific quality benchmarks.
SN - 0013-726X
SN - 1438-8812
ER -